Dr. Martens appoints Giles Wilson as new CFO

Dr. Martens plc

Dr. Martens plc (LON:DOCS) has announced that Giles Wilson has been appointed to the role of Chief Financial Officer (CFO). Giles will join Dr. Martens and take up his role in 2024, with the date to be confirmed and announced in due course.

Giles is an experienced CFO who joins Dr. Martens from William Grant & Sons Limited, one of the largest global spirits companies, owners of premium brands including Glenfiddich Scotch Whisky, The Balvenie Whisky and Hendrick’s Gin. Prior to this, Giles was at John Menzies plc as CFO (2016-20), and then subsequently became CEO (2019-20). Giles qualified as a chartered accountant with PwC and previously held a senior role at Commercial Estates Group.

Paul Mason, Chair, said “Following a rigorous selection process, we are delighted to appoint Giles as CFO. He is a very capable finance leader with extensive experience in a number of sectors and, most recently, his time in the branded spirits industry has given him a good grounding in global brands and wholesale distribution management. His knowledge of the public markets will be a valuable asset to the team as Dr. Martens continues its growth in the listed environment. I look forward to him joining the Board.”

Kenny Wilson, CEO, said “I am thrilled that Giles will be joining the leadership team and the Board. He brings a range of complementary skills and past experience that is highly relevant to our brand-first strategy. I am looking forward to working with him on the next phase of Dr. Martens’ journey to become a £2billion revenue footwear brand.”

Giles Wilson said “Dr. Martens is an iconic brand I have long admired, and I have been impressed by the passion and ambition within the business. I am excited to be joining at such an important stage in the Company’s growth and I am looking forward to working with Kenny and the team to drive the strategy forward.”

Jon Mortimore, who is retiring from the Company as previously announced, has agreed to stay with the business until the end of the financial year.

Remuneration Arrangements

Giles Wilson’s remuneration arrangements have been set in accordance with the Directors’ Remuneration Policy detailed in the FY23 Annual Report.  Further details will be set out in the Directors’ Remuneration Report for FY24.

Share on:

Latest Company News

Dr. Martens appoints Berenberg as Joint Corporate Broker

Dr. Martens plc has appointed Berenberg as a joint corporate broker with immediate effect, working alongside Investec and Goldman Sachs.

Dr. Martens Plc expands into UAE and Latin America through new partnerships

Dr. Martens has signed a distribution deal with Beside Group to enter the UAE market for the first time and partnered with Crosby in Latin America, which has opened stores in Argentina and Chile.

Dr Martens Plc AGM: Steady trading with DTC growth

Trading since the start of FY26 has met expectations across channels. Americas DTC saw strong full-price sales while APAC, notably South Korea, delivered robust growth; EMEA DTC, particularly the UK, remains challenging.

Dr. Martens Plc FY25 profit drops to £8.8m

Dr. Martens plc shares strong preliminary results for FY25, outlining a strategic roadmap—Levers For Growth—aimed at returning to profit growth and elevating brand desirability.

Dr. Martens Plc revenue down 18%, in line with expectations

Dr. Martens (LON:DOCS) reports first half results aligning with expectations, highlighting strategic progress in marketing, cost reduction, and U.S. growth.

Dr. Martens plc revenue down 12%, continued weak USA consumer demand

Dr. Martens plc (LON:DOCS) reports FY24 results impacted by weak USA consumer demand. Strategic plan in place to drive USA demand for future growth.

    Search

    Search